Prevalence and Risk Factors for Acute Kidney Injury in COVID-19-Hospitalized Patients in Poland Across Three Pandemic Periods

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1384 - 1384

Published: Feb. 19, 2025

Background/Objectives: Acute kidney injury (AKI) is a serious and prevalent complication of COVID-19. This study examines the prevalence, risk factors, outcomes AKI in hospitalized COVID-19 patients. Methods: We analyzed data 1223 adult patients from single district hospital during three pandemic periods: 3 November 2020-31 December 2020, 17 March 2021-8 May 2021, 4 2021-21 February 2022. The analysis included demographic data, comorbidities, laboratory results, chest radiographs (CT lung scans), outcomes. Results: found an overall incidence 29.02%. versus non-AKI ones were significantly older (median age 76.0 vs. 71.0, p < 0.001) had more especially previous renal diseases, heart failure, coronary artery disease, hypertension; they also often used diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACE-Is). frequently presented with abnormal CT scans higher white blood cell counts, lower lymphocytes percentages, C-reactive protein (CRP) levels, platelet counts. They required oxygen therapy, days hospitalization, mortality rates. Conclusions: Older age, use renin-angiotensin system (RASI) are key factors for AKI, which consequently linked to severe disease course poorer prognosis.

Language: Английский

Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: March 13, 2025

This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020–July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for relationship between COVID-19 vaccination Post-COVID-19 Condition (PCC) by timing relative to infection or PCC-onset. Comparisons vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) study characteristics known impact burden VE other endpoints were possible 31 studies where preceded infection. Seventy-seven percent pre-infection aVE statistically significant (range: 7%–95%). Statistically slightly higher mRNA 14%–84%) than non-mRNA vaccines 16%–38%) ranges before during Omicron overlapped. Our findings suggest SARS-CoV-2 reduces risk regardless type, number doses received, definition, predominant variant, severity acute infections included.

Language: Английский

Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A Systematic Literature Review

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Abstract Importance Existing systematic literature reviews (SLRs) on COVID-19 vaccine effectiveness (VE) against post-COVID-19 conditions (PCC) document high heterogeneity across studies, but have not compared VE design features known to impact PCC burden or other endpoints. Objective This SLR summarizes the evidence studies among predominately adults that report an adjusted measure of association for relationship between vaccination and PCC, by timing relative infection PCC-onset different study characteristics. Evidence review A comprehensive search strategy was developed within OVID platform EMBASE, MEDLINE® Evidence-Based Medicine reviews, supplemented with WHO COVID library Google Scholar® searches, collate published posted as pre-prints January 1 st , 2020 July 18 th 2023. JBI Critical Appraisal Checklists were used assess each study’s risk bias. Findings included 97 synthesized results from 56 low bias reported measures PCC. Overall, 77% pre-infection (aVE) estimates (vs. unvaccinated) statistically significant (range: 7%–95%), 80% reflecting a mix those vaccinated before after 62%–73%), one five onset (aVE=41%), 43% post-infection (two protective [range: 28%–40%] [aVE=-47%]), 46% specifying (23 29%–75%] [aVE=-132%]). Statistically aVE slightly higher mRNA 14%–84%) than non-mRNA vaccines 16%–38%) ranges during (4 studies; range: 10%–70%) Omicron predominance (10 7%–50%) overlapped. Pre-infection regardless type, number doses received, definition, predominant variant, severity acute infections included. Conclusions Relevance Collectively our findings suggest received prior SARS-CoV-2 reduces subsequent developing variant circulating. Key points Question Do vary onset, type disease severity? appeared reduce unvaccinated). Compared types, seemed offer greater protection, dose response observed vaccines. Meaning Despite reduced ≥1 proportion sample hospitalized, definition.

Language: Английский